Genmab A/S (GMAB) published its 2025 annual report and projected higher revenue for 2026, supported by royalty growth and strong product sales.
The biotechnology company expects 2026 revenue in the range of $4.065 billion to $4.395 billion, compared with $3.720 billion in 2025. Operating profit for 2026 is projected between $0.90 billion and $1.40 billion, while operating expenses are forecast at $2.710 billion to $2.910 billion.
For 2025, Genmab reported revenue of $3.72 billion, up 19% from $3.12 billion a year earlier, driven by higher royalties from DARZALEX and Kesimpta and increased EPKINLY sales. Royalty revenue rose 23% to $3.10 billion, while operating profit excluding acquisition-related items climbed to $1.26 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.